FLAI induction regimen in elderly patients with acute myeloid leukemia

Leuk Lymphoma. 2019 Dec;60(13):3339-3340. doi: 10.1080/10428194.2019.1620943. Epub 2019 Jun 4.

Authors

Marco Cerrano^{1

2}, Anna Candoni³, Elena Crisà^{1

2}, Maria Vittoria Dubbini³, Stefano D'Ardia², Maria Elena Zannier³, Mario Boccadoro^{1

2}, Ernesta Audisio², Benedetto Bruno^{1

4}, Dario Ferrero^{1

2}

Affiliations

¹ Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
² Department of Oncology, Division of Hematology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
³ Division of Hematology and SCT, University of Udine, Udine, Italy.
⁴ Department of Oncology, SSD Trapianto Allogenico, AOU Città della Salute e della Scienza di Torino, Turin, Italy.

PMID: 31159609
DOI: 10.1080/10428194.2019.1620943

No abstract available

Publication types

Letter

MeSH terms

Age Factors
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Chemotherapy, Adjuvant / adverse effects
Chemotherapy, Adjuvant / methods
Cytarabine / administration & dosage
Cytarabine / adverse effects
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Hematopoietic Stem Cell Transplantation*
Humans
Idarubicin / administration & dosage
Karyotyping
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Neoadjuvant Therapy / adverse effects
Neoadjuvant Therapy / methods*
Remission Induction / methods*
Retrospective Studies
Sex Factors
Time Factors
Transplantation, Homologous
Vidarabine / administration & dosage
Vidarabine / adverse effects
Vidarabine / analogs & derivatives

Substances

Cytarabine
Vidarabine
fludarabine
Idarubicin